[Ip-health] Drug Price Gouging suit

Sean Flynn sflynn at wcl.american.edu
Fri Jun 23 11:04:37 PDT 2017


A blood cancer patient has accused drug company Celgene Corp. of abusing consumer safety rules and maintaining a monopoly over its expensive treatments to prevent the creation of lower-cost generics (International Union of Operating Engineers Stationary Engineers Local 39 Health & Welfare Fund et al v. Celgene Corporation, D.N.J., No. 2:17-cv-04319, filed 6/14/17).

Sean Flynn
Director, LLM in Intellectual Property
Acting Director, Program on International Organizations, Law and Diplomacy
Associate Director, Professorial Lecturer in Residence, Program on Information Justice and Intellectual Property
American University Washington College of Law




More information about the Ip-health mailing list